Liu Jiaxin, Yang Yang, Qi Yun
Department of Endocrinology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, China.
Front Nutr. 2024 Mar 15;11:1349006. doi: 10.3389/fnut.2024.1349006. eCollection 2024.
This meta-analysis was conducted to investigate the impact of saffron supplementation on the glycemic outcomes in patients with diabetes.
Eight electronic databases were systematically searched from inception to March 31, 2023. RCTs of patients with diabetes receiving saffron compared with placebo which reported glycemic control outcomes were identified. WMD and 95% CIs were pooled using fixed-effects or random-effects models, depending on the significance of heterogeneity.
Out of the 837 citations screened, ten RCTs were included in the systematic review and meta-analysis. A total of 562 participants were enrolled, with 292 assigned to the intervention group and 270 to the control group. Saffron was administered at a dose of 5 mg/day to 1 g/day. Compared with placebo, saffron supplementation significantly reduced FPG (WMD = -8.42 mg/dL; 95% CI: -13.37, -3.47; = 0.001) and HbA1c (WMD = -0.22%; 95% CI: -0.33, -0.10; < 0.001). However, there was no significant effect on insulin levels, QUICKI and HOMA-IR.
Saffron is effective for patients with diabetes in terms of FPG and HbA1c, therefore, it appears to be a promising adjuvant for the glycemic control of DM. However, the overall methodological quality of the identified studies is heterogeneous, limiting the interpretation of the benefit of saffron in diabetes. More long-term follow-up, well-designed and large-scale clinical trials are warranted to draw definitive conclusions.
The protocol of review was registered in International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42023426353).
本荟萃分析旨在研究补充藏红花对糖尿病患者血糖结果的影响。
系统检索了8个电子数据库，检索时间从数据库建立至2023年3月31日。纳入了比较接受藏红花治疗的糖尿病患者与接受安慰剂治疗的患者的随机对照试验，这些试验报告了血糖控制结果。根据异质性的显著性，使用固定效应或随机效应模型汇总加权均数差（WMD）和95%可信区间（CIs）。
在筛选的837篇文献中，有10项随机对照试验被纳入系统评价和荟萃分析。共纳入562名参与者，其中292名被分配到干预组，270名被分配到对照组。藏红花的给药剂量为每天5毫克至1克。与安慰剂相比，补充藏红花显著降低了空腹血糖（WMD = -8.42毫克/分升；95% CI：-13.37，-3.47；P = 0.001）和糖化血红蛋白（WMD = -0.22%；95% CI：-0.33，-0.10；P < 0.001）。然而，对胰岛素水平、定量胰岛素敏感性检查指数（QUICKI）和稳态模型评估胰岛素抵抗指数（HOMA-IR）没有显著影响。
藏红花在空腹血糖和糖化血红蛋白方面对糖尿病患者有效，因此，它似乎是糖尿病血糖控制的一种有前景的辅助药物。然而，已识别研究的总体方法学质量存在异质性，限制了对藏红花在糖尿病中益处的解释。需要更多长期随访、设计良好的大规模临床试验来得出明确结论。
该评价方案已在国际前瞻性系统评价注册库（PROSPERO）中注册（注册号：CRD42023426353）。
